Qualigen Therapeutics, Inc. news

Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug designation, while also commercializing diagnostics, today announces the mutual extension of a research agreement with University of Louisville Research Foundation (ULRF). The revised agreement expands the Company’s collaboration with the research institution to develop its ongoing RAS-F platform currently in the

Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a biotechnology company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, today announces that three abstracts on aspects of the Company’s recently in-licensed compound from University College -London, QN-302, have been accepted as posters to be presented at the prestigious American Association of Cancer Research (AACR) conference in April. QN-302 (previously known as SOP1812) is the C

Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a biotechnology company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, today announced that it has engaged Professor Stephen Neidle as a scientific advisor. Professor Neidle is a world-renowned scientist at University College London and is the key innovator of the Company’s in-licensed genomic quadruplex (G4)-selective transcription inhibitor platform. Qualigen is developing this pl

Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a biotechnology company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, today announces the exclusive worldwide in-license of a genomic quadruplex (G4)-selective transcription inhibitor drug development program, including lead and back-up compounds, preclinical data and a patent estate, from University College London (UCL). Qualigen intends to develop the lead compound, now called QN-302,

Qualigen Therapeutics, Inc. (NASDAQ: QLGN), a biotechnology company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, announced today that CEO and Chairman Michael Poirier will present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit September 20-23, 2021.

The presentation will provide an overview of the Company’s strategy focusing primarily on its oncology drug pipeline which includes QN-247 and RAS